ABSTRACT
Grape seed extract (GSE) supplement use is becoming more popular today for its potential chemopreventive and chemotherapeutic role. We report a 49-year-old male who presented with recurrent nausea, vomiting, diarrhea, and acute weakness following GSE use. A thorough medical workup ensued and no causes were identified clinically, procedurally, or with imaging. Symptoms resolved after GSE discontinuation and the patient remained symptom-free 5 years later. This case illustrates the paucity of documented detailed clinical cases and lack of controlled trials detailing a thorough and reproducible adverse effect profile of GSE supplement.
Subject(s)
Dietary Supplements/adverse effects , Grape Seed Extract/adverse effects , Diarrhea/etiology , Diarrhea/physiopathology , Follow-Up Studies , Humans , Male , Middle Aged , Nausea/etiology , Nausea/physiopathology , Vitis/chemistry , Vomiting/etiology , Vomiting/physiopathologyABSTRACT
Chronic watery diarrhea combined with normal-appearing colonic mucosa at endoscopy with abnormal histopathology is classified as microscopic colitis. Microscopic colitis encompasses both collagenous and lymphocytic colitis. A 42-year-old Caucasian woman presented with severe diarrhea for six weeks with loose watery stools every 1-2 h, approximately 15 episodes per day. She denied any melena or significant abdominal pain. She denied nonsteroidal anti-inflammatory drug or lansoprazole use, and was only taking diphenoxylate/atropine for her symptoms. Colonoscopy revealed superficial ulcerations in the distal ascending and transverse colon and scattered ulcerations in the descending and sigmoid colon, with biopsy confirming collagenous colitis. We report a rare case of collagenous colitis accompanied by mucosal ulcerations in the absence of known culprits of mucosal ulcerations, such as nonsteroidal anti-inflammatory drugs or lansoprazole.
Subject(s)
Gastritis/diagnosis , Gastritis/pathology , Helicobacter Infections/diagnosis , Helicobacter Infections/pathology , Helicobacter/classification , Helicobacter/isolation & purification , 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Adolescent , Anti-Bacterial Agents/therapeutic use , Biopsy , Clarithromycin/therapeutic use , Endoscopy, Digestive System , Gastric Mucosa/pathology , Gastritis/microbiology , Helicobacter Infections/microbiology , Histocytochemistry , Humans , Male , Metronidazole/therapeutic use , Microscopy , Pantoprazole , Proton Pump Inhibitors/therapeutic useABSTRACT
Preliminary results indicate that living donor liver transplantation patients infected with hepatitis C virus (HCV) develop earlier and more severe recurrence than their cadaveric counterparts. The mechanisms underlying this observation are unknown, but could include hepatic regeneration, differences in living donor liver transplantation recipient demographics, immune homology between donor and recipients, or other factors not previously considered. The optimum clinical approach is to only consider living donor liver transplantation in HCV-infected recipients as a life-saving procedure and to attempt to eradicate HCV before transplantation to prevent recurrent infection.
